Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine plus psychotherapy for borderline personality disorder
ACTRN12615000705583Phase 3Withdrawn
- Sponsor
- Eastern Health
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in borderline personality disorder (BPD) comparing Quetiapine then quetiapine plus psychotherapy with Placebo then placebo plus psychotherapy (2 arms). Primary endpoint: Borderline symptom severity. Planned start Mar 2016; status: withdrawn.
02
Drugs
quetiapine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on ACTRN12615000705583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000705583.